Su1075 Factors Determining Adenoma Detection Rate (ADR) in Randomized Controlled Trials of Bowel Cleansing Regimens Prior to Colonoscopy. A Meta-Regression Analysis Based on a Clinical Trial Database

2015 ◽  
Vol 148 (4) ◽  
pp. S-400
Author(s):  
Wolfgang Fischbach ◽  
Juergen Pohl ◽  
Ansuya Naidoo ◽  
Jonathan Belsey
Keyword(s):  
Clinical Trial ◽  
Regression Analysis ◽  
Randomized Controlled Trials ◽  
Detection Rate ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Adenoma Detection ◽  
Bowel Cleansing ◽  
Meta Regression ◽  
Meta Regression Analysis

scholarly journals SOFA and mortality endpoints in randomized controlled trials: a systematic review and meta-regression analysis

Critical Care ◽  
2017 ◽  
Vol 21 (1) ◽  
Author(s):  
Harm-Jan de Grooth ◽  
Irma L. Geenen ◽  
Armand R. Girbes ◽  
Jean-Louis Vincent ◽  
Jean-Jacques Parienti ◽  
...  
Keyword(s):  
Systematic Review ◽  
Regression Analysis ◽  
Randomized Controlled Trials ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Meta Regression ◽  
Meta Regression Analysis

Statins and Cancer Risk: A Literature-Based Meta-Analysis and Meta-Regression Analysis of 35 Randomized Controlled Trials

2006 ◽  
Vol 24 (30) ◽  
pp. 4808-4817 ◽  
Author(s):  
Stefanos Bonovas ◽  
Kalitsa Filioussi ◽  
Nikolaos Tsavaris ◽  
Nikolaos M. Sitaras
Keyword(s):  
Regression Analysis ◽  
Cancer Risk ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Meta Regression ◽  
Meta Regression Analysis ◽  
Risk Of Cancer ◽  
Statin Use

Purpose A growing body of literature suggests that statins may have chemopreventive potential against cancer. Our aim was to examine the strength of this association through a detailed meta-analysis and meta-regression analysis of randomized controlled trials (RCTs). Methods A comprehensive search for trials published up to 2005 was performed, reviews of each study were conducted, and data were abstracted. Before meta-analysis, the studies were evaluated for publication bias and heterogeneity. Pooled relative risk (RR) estimates and 95% CIs were calculated using the random- and fixed-effects models. Subgroup, sensitivity, and meta-regression analyses were also conducted. Results Thirty-five RCTs of statins for cardiovascular outcomes contributed to the analysis (n = 109,143). The degree of variability between trials was consistent with what would be expected to occur by chance alone. Statin use was not associated with a substantially increased or decreased overall risk of cancer (RR = 0.99; 95% CI, 0.94 to 1.04). Similarly, statin use did not significantly affect respiratory cancer risk (RR = 0.95; 95% CI, 0.83 to 1.09). However, the meta-regression analysis indicated that age of study participants modified the association between statin use and cancer risk (P = .003). Conclusion Our findings do not support a protective effect of statins against cancer. However, this conclusion is limited by the relatively short follow-up periods (4.5 years on average) of the studies analyzed. Thus, it is important to continue monitoring the long-term safety profiles of statins. Until then, physicians need to be vigilant in ensuring that statin use remains restricted to the approved indications.

scholarly journals M201. MODERATORS OF WEIGHT GAIN IN RANDOMIZED CONTROLLED TRIALS OF SCHIZOPHRENIA – A META-REGRESSION ANALYSIS

2020 ◽  
Vol 46 (Supplement_1) ◽  
pp. S212-S213
Author(s):  
Johannes Schneider-Thoma ◽  
Irene Bighelli ◽  
Spyridon Siafis ◽  
Stefan Leucht
Keyword(s):  
Weight Loss ◽  
Regression Analysis ◽  
Weight Gain ◽  
Randomized Controlled Trials ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Study Duration ◽  
Baseline Weight ◽  
Meta Regression ◽  
Meta Regression Analysis

Abstract Background Weight gain is an important side effect of antipsychotics. Meta-analyses of randomized controlled trials indicate differences between the multiple antipsychotics in propensity to cause weight gain. However, antipsychotic-associated weight gain, in randomized controlled trials as well as in real life situations, might also depend on population characteristics and treatment-related factors. As a preparatory work for a systematic review and network-meta-analysis on metabolic side effects of antipsychotics (presented in another poster at this conference), we conducted a meta-regression analysis of potential moderators of weight gain. Methods We selected acute phase short-term, acute phase long-term as well as relapse prevention studies (all found by systematic reviews conducted by our group in the past) from our database of randomized controlled trials of antipsychotics in schizophrenia. We conducted We examined the moderators baseline weight, study duration, percentage women, and publication year. We conducted the analyses for all drugs pooled, placebo and per individual drug. For presentation of the results we focus on the drugs aripiprazole, haloperidol, quetiapine, olanzapine, and risperidone, because these are popular drugs in clinical practice, they differ in their receptor-binding profiles and multiple studies are available for these drugs. We conducted the analysis in R using the commands metacont, metagen and metareg from the package meta. Results The dataset comprises 603 randomized controlled trials with 141 584 patients that examined 40 different antipsychotics. Trial duration varied between 3 and 156 weeks (median 8 weeks). 168 studies with 49 670 patients reported on change in body weight. We found no effect of baseline weight on antipsychotic-associated weight gain, however on placebo, lower baseline weight was associated with more weight loss. Moreover, on antipsychotics, higher percentage of women was associated with less weight gain, and, on placebo, higher percentage of women was associated with more weight loss. Longer study duration was not associated with increased weight gain. On placebo, longer studies were associated with more weight loss. There was no effect of publication year. Discussion Surprisingly, we found no moderating effect of baseline weight and study duration on weight gain. However, our data suggests that men and women could have different risk of weight gain. Moreover, weight loss after switching to placebo might be higher in women and patients with less baseline weight. For interpretation, it must be noted that meta-regressions are observational evidence and thus prone to confounding. In addition, the scatter plots, presented on the poster, need to be considered to judge the robustness and magnitude of the moderated effects. Additional meta-regressions (planned to present on the poster) should address further potential moderators, such as antipsychotic dose, ethnicity, previous antipsychotic exposure and dropout rates.

Sign in / Sign up

Export Citation Format

Share Document